2 assets in Oral Cavity Cancer

Therapeutic assets addressing Oral Cavity Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Oral Cavity Cancer	VM Oncology, LLC	P1/2	CCC (48)
Pembrolizumab Oral Cavity Cancer	VM Oncology, LLC	P1/2	CCC (48)